This site is intended for healthcare professionals
Industry news

Seattle Genetics acquires Cascadian Therapeutics and with it tucatinib a tyrosine kinase inhibitor to treat Breast Cancer

Read time: 1 mins
Last updated:1st Feb 2018
Published:1st Feb 2018
Source: Pharmawand
Register free for full access to medthority.com